首页 > 抗体蛋白 > 抗体
Brilliant Violet 421™ anti-mouse CD3&epsilon
产品名称:
Brilliant Violet 421™ anti-mouse CD3&epsilon
产品类别:
抗体
产品编号:
100335
产品应用:
100335
[价格]
规格 价格 库存
125µL ¥ 2112 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The immunoglobulin was purified by affinity chromatography and conjugated with Brilliant Violet 421? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
ICC - Verified

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. For immunocytochemistry using the ?l sizes, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32, ?and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  2. Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed
  3. Ren Z, et al. 2021. EMBO Molecular Medicine. :e14059. PubMed
  4. Yang N, et al. 2022. NPJ Vaccines. 7:120. PubMed
  5. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  6. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  7. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  8. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  9. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  10. Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed
  11. Nakagawa S et al. 2017. Cell host & microbe. 22(5):667-677 . PubMed
  12. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  13. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  14. Kuang Z, et al. 2020. Antib Ther. 3:227. PubMed
  15. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  16. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  17. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  18. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  19. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  20. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  21. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  22. Formaglio P, et al. 2021. Immunity. 54:2724. PubMed
  23. Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed
  24. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  25. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  26. Lee C, et al. 2015. Nat Commun. 6: 8477. PubMed
  27. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  28. Qi F, et al. 2019. Front Microbiol. 2.140277778. PubMed
  29. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  30. Kiyohara H, et al. 2018. Cell Mol Gastroenterol Hepatol. 7:135. PubMed
  31. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  32. Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed
  33. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  34. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
  35. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  36. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
  37. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  38. Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed
  39. Kumar D, et al. 2018. Cancer Prev Res (Phila). 0.895138889. PubMed
  40. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  41. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  42. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  43. Goc J, et al. 2021. Cell. :. PubMed
RRID
AB_10898314 (BioLegend Cat. No. 100335) AB_2562556 (BioLegend Cat. No. 100341) AB_11203705 (BioLegend Cat. No. 100336)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线